


is for ADULT AND PEDIATRIC PATIENTS with solid tumors where an NTRK gene fusion has been identified





**VITRAKVI** 

## **TREAT**

Favorable long-term safety profile has been demonstrated



majority of AEs were **Grade 1 or 2** in severity <sup>4</sup>



discontinuation rate due to treatment-related AEs <sup>4</sup>



of patients had a dose reduction due to AEs <sup>4</sup>

Date cut-off: Feb 18, 2019

### TRANSFORM

Fusion Positive. Positive Result.



months median time to response (range: 0.9 – 6.6 months) <sup>5</sup>



Objective response rate: (95% CI: 71, 84) <sup>5</sup>



Survival endpoints at 12 months: 69% PFS and 90% OS <sup>5</sup>



months median PFS (95% CI: 25.7, NE) with a median follow-up of 13.8 months 5

Date cut-off: July 15, 2019

# $\label{limits} VITRAKVI\ \ is\ available\ as\ capsules\ and\ oral\ solutions\ for\ both\ adults\ and\ children$

Vitable Abbeviolated Practibing information.

Literative of the Commission of the Co

- Interesce:

  VIRMANI Hong Kong Product Information, September 2019.

  Valatina M. Ja A. T. Dosebe R.C. Tilling down an old oncopage in in one en of targetes through Curver Discov. 2015; 5(1): 25-34.

  Valatina M. J. L. A.T. Dosebe R.C. Tilling down an old oncopage in in the series and entire through Curver Discov. 2015; 5(1): 25-34.

  Hong D.S. et al. Lanceton in patients with This bouns positive double nours as pooled analysis of three place 21.0 Calinotal trials. Lancet Oncol. 2002;14(1): 513-540.

  Hong D.S. et al. Lanceton in patients with This bouns positive double nours as pooled analysis of three place 21.0 Calinotal trials. Lancet Oncol. 2002;21(4): 511-540.

  Hong D.S. et al. Lanceton in patients with This bouns positive double dataset of patients with TRR fusion cancer. Poster presented at: European Society for Medical Crocology Virtual Congress; Septer 2020. Annical Of Concept (2002) 2(1); 2(1); 4(1)





TEST. TREAT. TRANSFORM.